Cutibacterium acnes AD3 Propionic Acid Anti-Inflammatory Skin Barrier
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for atopic dermatitis (AD) are limited by side effects, short-term efficacy, and the need for long-term management of chronic inflammation and skin barrier dysfunction.
Innovation Solution
The use of Cutibacterium acnes AD3, which produces high yields of propionic acid, as a topical treatment to inhibit inflammatory factors, promote skin barrier function, and stabilize the skin microbiota.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical corticosteroids are used for long-term treatment, then anti-inflammatory effect is improved, but skin atrophy and pigmentation abnormalities occur
Solution Approach 1:
The patent utilizes Cutibacterium acnes, a bacterium traditionally considered pathogenic in acne conditions, and transforms it into a beneficial therapeutic agent for atopic dermatitis. The bacterium produces propionic acid and other metabolites that exert anti-inflammatory effects, converting a harmful microorganism into a protective therapeutic tool that avoids the side effects of conventional corticosteroids
Solution Approach 2:
The patent changes the therapeutic parameter from exogenous anti-inflammatory drugs (corticosteroids) to endogenous metabolites produced by C. acnes (propionic acid, short-chain fatty acids). This parameter change provides sustained anti-inflammatory action through continuous metabolite production by the colonizing bacterium, eliminating the need for repeated drug applications and avoiding cumulative side effects
2Reliability
If topical calcineurin inhibitors are used for long-term treatment, then anti-inflammatory effect is improved, but risk of skin malignancies increases
Solution Approach 1:
The patent transforms C. acnes from a potential pathogen into a protective agent that produces anti-inflammatory metabolites. These naturally-produced metabolites (propionic acid, short-chain fatty acids) provide immunomodulation without the carcinogenic risks associated with synthetic calcineurin inhibitors, offering a safer long-term therapeutic option
3Reliability
If oral immunosuppressants are used for treatment, then systemic anti-inflammatory effect is improved, but severe toxicity and side effects occur
Solution Approach 1:
The patent employs C. acnes as a self-service therapeutic agent that colonizes the skin and continuously produces anti-inflammatory metabolites (propionic acid, short-chain fatty acids) in situ. This eliminates the need for systemic immunosuppressant administration, providing localized sustained therapy without the severe systemic toxicity and side effects associated with oral medications
Solution Approach 2:
The patent converts C. acnes, traditionally viewed as a pathogenic bacterium, into a beneficial probiotic agent. The bacterium's natural metabolic activities produce therapeutic metabolites that provide anti-inflammatory effects locally, avoiding the need for systemic immunosuppression and its associated severe toxicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Cutibacterium acnes AD3 effectively reduces inflammation, suppresses pruritus, enhances skin barrier function, and promotes the balance of skin symbiotic microbiota, offering a safe and sustainable therapeutic option for AD.
Implementation Method 1
Cutibacterium acnes strain, which produces high yields of propionic acid
Implementation Method 2
inhibit inflammatory factors, promote skin barrier function, and stabilize the skin microbiota
Data Source
Figure 1~3
Figure 4F~6H
Figure 7I~9F
AI summary
The present invention provides a Cutibacterium acnes AD3 strain, GDMCC No: 62625. The strain features high propionic acid yields, and can be used for preparing a product for treating an inflammation-related skin disease and improving skin conditions.